Tue, Aug 4, 2015
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Regulation, market conditions drive product offerings in Malta

Thursday, May 22, 2014

amb
Xavier Urli
Bailey McCann, Opalesque New York:

The wave of regulation hitting European market participants is now driving product and portfolio conversations between managers and investors according to participants in the latest Opalesque Malta Roundtable. Delegates note that product designations like UCITS or PIF are now among the first items investors ask about when working with a manager.

"One trend we have observed as an investment manager is that clients now really look at the regime or product regulation like UCITS or AIFMD. That leads to a real sort of segmentation within the offerings of a fund manager, where according to the client’s needs the solutions you are tailoring for them will be driven not only by the investment strategies but also by the regime under which the client wants the investment to be done," says Xavier Urli, of Innocap Global Investment Management.

"Especially in the EU, the discussion is now revolving around deciding what type of regime and product you'll be using – UCITS, AIFMD, PIF – what distribution, what jurisdiction, etc. These discussions will only become more relevant going forward, until, maybe, at some point things settle down a bit."

Beyond particular fund wrappers instruments like derivatives are also seeing questions, with most parties now asking for products like FX derivatives to be traded on listed portfolios. This trend is n......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Activist News - Celgene says patent-fighting hedge fund manager wants to short its shares[more]

    From Reuters.com: Celgene Corp, one of the world's largest biotechnology companies, has accused U.S. hedge fund manager Kyle Bass of attempting to profit from his attempts to wipe out several major drug patents through his Coalition for Affordable Drugs. The company asked the U.S. Patent and T

  2. Einhorn's Greenlight Capital hedge fund slumps 6.1 percent in July[more]

    From Reuters/Thefiscaltimes.com: Hedge fund mogul David Einhorn's Greenlight Capital slumped 6.1 percent in July and is now down 9 percent for the year after gold, one of the fund's top holdings, tumbled to five-year lows last week. Greenlight notified clients of its returns late on Friday, ac

  3. Performance - Some hedge fund small-cap energy stocks have been free falling, Dan Loeb's simple strategy destroys the market, Baupost lost 1.4% last quarter as energy bargains proved elusive[more]

    Some hedge fund small-cap energy stocks have been free falling From Marketrealist.com: According to a July 28, 2015, Bloomberg article, there was a 34% fall in small-cap energy stocks over the past three months. These shares are tracked by the Russell 2000 Energy Index. Small-cap energy

  4. Legal - Hedge funds hit Rothstein Kass with $75m malpractice suit, JPMorgan questioned on private bank’s hedge fund disclosures, Kijani fund, seized by regulators in Cayman Islands, spotlights risks in lightly regulated market[more]

    Hedge funds hit Rothstein Kass with $75m malpractice suit From Law360.com: Two investment funds have sued Rothstein Kass & Co. PC for at least $75 million, claiming the New Jersey auditing firm committed accounting malpractice by failing to properly scrutinize overblown valuations of the

  5. Assets - Hedge funds are getting smoked by the commodities slump, Global ETF assets could more than double by 2020[more]

    Hedge funds are getting smoked by the commodities slump From Businessinsider.in: The collapse in commodity prices has burnt another hedge fund. Vermillion, a commodity hedge fund backed by Carlyle Group, has seen its flagship fund's assets fall from nearly $2 billion to less $50 million,

 

banner